Business Information
The group's principal activity is to design, develop, market and support science- and technology-based products and services. The group operates under two segments: software segment and drug discovery segment. Through accelrys inc the group develops and commercializes molecular modeling, simulation, informatics, and decision support software for the life sciences and materials research markets. Through pharmacopeia drug discovery, inc. It integrates proprietary small molecule combinatorial and medicinal chemistry, high-throughput screening, in-vitro pharmacology, computational methods and informatics to discover and optimize lead compounds. Customers include pharmaceutical, biotechnology, chemical, petroleum and semiconductor companies, governmental institutions and universities. On 30-Apr-2004, the group discontinued pdd operations. On 28-Sep-2004, the group acquired scitegic, inc.
|
|
Name |
Title
|
Email
|
| Kenneth Coleman | Chmn. | N/A | | Mark Emkjer | Dir., CEO, Pres. | N/A | | Frank Brown | Chief Science Officer | N/A | | Rick Russo | CFO, Sr. VP | N/A | | David Mersten | Sr. VP, General Counsel, Sec. | N/A |
|
|
Year |
Sales |
Net Income |
| 2007 | 80,955 | (1,525) | | 2006 | 82,001 | (7,739) | | 2005 | 69,631 | (25,172)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
